Stay updated with breaking news from Systemic Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
25 years of serving the community
25 years of serving the community
Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
The global malignant pleural effusion market is expected to garner a market value of US$ 4.5 Billion in 2023 and is expected to accumulate a market value of US$ 8.06 Billion by registering a CAGR of 6% in the forecast period 2023-2033. The increasing incidence of pleural effusion disease and rising awareness of adva...